ClinicalTrials.gov record
Completed Phase 2 Interventional

Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting

ClinicalTrials.gov ID: NCT01946477

Public ClinicalTrials.gov record NCT01946477. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 11:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multicenter, Multi-cohort, Open-label Study of Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide Based Therapy in the First or Second Line Setting.

Study identification

NCT ID
NCT01946477
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Celgene
Industry
Enrollment
186 participants

Conditions and interventions

Interventions

  • Daratumumab Drug
  • Dexamethasone Drug
  • Pomalidomide Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 28, 2014
Primary completion
Apr 29, 2025
Completion
May 25, 2025
Last update posted
Jun 5, 2025

2014 – 2025

United States locations

U.S. sites
33
U.S. states
18
U.S. cities
31
Facility City State ZIP Site status
Local Institution - 126 Tucson Arizona 85724
Local Institution - 137 Greenbrae California 94904-2007
Local Institution - 109 Los Angeles California 90095-1670
Local Institution - 104 Pleasant Hill California 94523
Local Institution - 108 Whittier California 90603
Local Institution - 138 Denver Colorado 80218
Local Institution - 120 Stamford Connecticut 06902
Local Institution - 145 Jacksonville Florida 32256
Local Institution - 127 Orlando Florida 32804
Local Institution - 133 Pembroke Pines Florida 33028
Local Institution - 136 St. Petersburg Florida 33705
Local Institution - 134 Fairway Kansas 66205
Local Institution - 142 Topeka Kansas 66606
Local Institution - 124 Louisville Kentucky 40207
Local Institution - 103 Westminster Maryland 21157
Local Institution - 146 Gross Pointe Michigan 48236
Local Institution - 102 Kansas City Missouri 64111
Local Institution - 110 St Louis Missouri 63110
Local Institution - 118 East Orange New Jersey 07018
Local Institution - 101 Hackensack New Jersey 07601
Local Institution - 129 Glens Falls New York 12801
Local Institution - 149 The Bronx New York 10467
Local Institution - 130 Durham North Carolina 27705
Local Institution - 123 Cleveland Ohio 44106
Local Institution - 121 Cleveland Ohio 44111
Local Institution - 115 Cleveland Ohio 44195
Local Institution - 122 Mayfield Heights Ohio 44124
Local Institution - 107 Hershey Pennsylvania 17033-0850
Local Institution - 135 Chattanooga Tennessee 37404
Local Institution - 131 Nashville Tennessee 37203
Local Institution - 128 Lubbock Texas 79410
Local Institution - 143 Plano Texas 75093
Local Institution - 106 Spokane Washington 99218

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01946477, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 5, 2025 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01946477 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →